Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells

Leukemia

Volumn 19, Issue 12, 2005, Pages 2153-2158

  Xu, R H ^a,b   Pelicano, H ^a   Zhang, H ^a   Giles, F J ^a   Keating, M J ^a   Huang, P ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

ATP metabolism; Drug combination; Glycolysis; Rapamycin; Synergy

Indexed keywords

3 BROMO 2 OXOPROPIONIC ACID PROPYL ESTER; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CYTARABINE; ENZYME INHIBITOR; GLUCOSE; GLYCOLYTIC ENZYME; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PROPIONIC ACID DERIVATIVE; RAPAMYCIN; S6 KINASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; ENERGY METABOLISM; GLYCOLYSIS; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; LYMPHOMA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 28544444116     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2403968     Document Type: Article

References (22)

1. Warburg O. The Metabolism of Tumors. London: Constable Co. Ltd, 1930.
2. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314.
3. Zu XL, Guppy M. Cancer metabolism: Facts, fantasy, and fiction. Biochem Biophys Res Commun 2004; 313: 459-465.
4. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN et al. Inhibition of glycolysis in cancer cells: A novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 2005; 65: 613-621.
5. Geschwind JF, Georgiades CS, Ko YH, Pedersen PL. Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma. Expert Rev Anticancer Ther 2004; 4: 449-457.
6. Maher JC, Krishan A, Lampidis T. Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic condition. Cancer Chemother Pharmacol 2004; 53: 116-122.
7. Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF et al. 2-Deoxy-D-glucose increases the efficacy of Adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 2004; 64: 31-34.
8. Ko YH, Pedersen PL, Geschwind JF. Glucose catabolism in the rabbit VX2 model for liver cancer. Cancer Lett 2001; 173: 83-91.
9. Dennis PB, Jaeschke A, Saitoh M, Fowler B, Kozma SC, Thomas G. Mammalian TOR: A homeostatic ATP sensor. Science 2001; 294: 1102-1105.
10. Bjornsti MA, Houghton PJ. The TOR pathway: A target for cancer therapy. Nat Rev Cancer 2004; 4: 335-348.
11. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18: 1926-1945.
12. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000; 103: 253-262.
13. Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004; 22: 2336-2347.
14. Panwalkar A, Verstovsek S, Giles FJ. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 2004; 100: 657-666.
15. Dancey JE. Inhibitors of the mammalian target of rapamycin. Expert Opin Investig Drugs 2005; 14: 313-328.
16. Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS et al. Advanced cancers: Eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 2004; 324: 269-275.
17. Seymour JF, Huang P, Plunkett W, Gandhi V. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: Implications for a continuous infusion schedule. Clin Cancer Res 1996; 2: 653-658.
18. Chou TC, Hayball MP. CalcuSyn: Window software for dose effect analysis. Cambridge, United Kingdom: Biosoft.
19. Easton JB, Houghton PJ. Therapeutic potential of target of rapamycin inhibitors. Expert Opin Ther Targets 2004; 8: 551-564.
20. Huang L, Shu M, Dilling J, Easton F, Harwood H, Ichijo P et al. Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21Cip1. Mol Cell 2003; 11: 1491-1501.
21. Edinger AL, Thompson CB. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell 2002; 13: 2276-2288.
22. Peterson RT, Desai BN, Hardwick JS, Schreiber SL. Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein. Proc Natl Acad Sci USA 1999; 96: 4438-4442.